Literature DB >> 12469155

Measurement of serum thymidine phosphorylase levels by highly sensitive enzyme-linked immunosorbent assay in gastric cancer.

Soh Katayanagi1, Tatsuya Aoki, Yu Takagi, Kazushige Ito, Hideo Sudo, Akihiko Tsuchida, Yasuhisa Koyanagi.   

Abstract

Thymidine phosphorylase (TP) is an enzyme that converts 5'-DFUR to 5-FU and also acts as an angiogenic factor. Measurement of serum TP levels has recently become possible by highly sensitive enzyme-linked immunosorbent assay (ELISA). We examined 38 patients with gastric adenocarcinoma to measure serum TP levels by highly sensitive ELISA method and tissue TP levels by conventional ELISA. In addition, immunohistochemical staining of normal and cancer tissues was also performed. Serum TP levels in patients with stages III and IV and inoperable or recurrent cancer were significantly higher than those in healthy controls. A high correlation was found between serum TP levels and tumor TP levels (r=0.65, p<0.0001). Moreover, serum TP levels were about 1/2500 of tumor TP levels. Tissue TP values in tumor were significantly higher than those in normal tissue. On the other hand, no significant differences among the cancer stages were found in either serum or tumor tissue. In conclusion, we demonstrate that serum TP levels strongly reflect tumor TP levels, and it may predict clinicopathological factors, prognosis, or sensitivity of anti-cancer drugs.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12469155

Source DB:  PubMed          Journal:  Oncol Rep        ISSN: 1021-335X            Impact factor:   3.906


  2 in total

1.  Apoptosis induced by preoperative oral 5'-DFUR administration in gastric adenocarcinoma and its mechanism of action.

Authors:  Wen-He Zhao; Shi-Fu Wang; Wei Ding; Jian-Ming Sheng; Zhi-Min Ma; Li-Song Teng; Min Wang; Fu-Sheng Wu; Bing Luo
Journal:  World J Gastroenterol       Date:  2006-03-07       Impact factor: 5.742

2.  5-Nitrouracil stabilizes the plasma concentration values of 5-FU in colorectal cancer patients receiving capecitabine.

Authors:  Yoichiro Yoshida; Yasuhiro Hashimoto; Makoto Miyazaki; Naoya Aisu; Teppei Yamada; Ryuji Kajitani; Taro Munechika; Yoshiko Matsumoto; Hideki Nagano; Hideki Shimaoka; Akira Komono; Ryohei Sakamoto; Gumpei Yoshimatsu; Fumihiro Yoshimura; Fumiaki Kiyomi; Suguru Hasegawa
Journal:  Sci Rep       Date:  2020-02-17       Impact factor: 4.379

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.